LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
LQDA
Liquidia Corporation
There isn't enough reported data to score LQDA yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LQDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Strong | |
| Strong |
LQDA's revenue, cash flow and balance sheet are currently healthy, but its profitability is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LQDA PE Valuation
LQDA has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over LQDA on the outlook, with more favorable profitability expectations.
LQDA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for LQDA, but weaker profitability. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over LQDA on earnings quality, reporting a profit while its opponent remains loss making.
LQDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.15 | — |
| Q3 2026 | -$1.20 | +$0.23 |
| Q2 2026 | $1.40 | +$3.09 |
| Q1 2026 | $0.17 | +$1.74 |
| Q4 2025 | -$0.80 | +$0.86 |
| Q3 2025 | -$1.43 | +$0.21 |
| Q2 2025 | -$1.69 | -$0.11 |
| Q1 2025 | -$1.57 | $0.00 |
| Q4 2024 | -$1.66 | -$0.45 |
LQDA is still losing money, but far less than before: $1.20 per share over the past year, against $2.60 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LQDA on profitability, with a higher operating margin.
LQDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $225.3M | +315% |
| Q2 2026 | $171.7M | +1843% |
| Q1 2026 | $132.9M | +4158% |
| Q4 2025 | $92M | +3055% |
| Q3 2025 | $54.3M | +1122% |
| Q2 2025 | $8.8M | +142% |
| Q1 2025 | $3.1M | +5% |
| Q4 2024 | $2.9M | -36% |
LQDA's revenue has grown year over year for seven quarters in a row: $225M last quarter, up 315% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -117% | -120 points |
| Q2 2026 | 50% | +474 points |
| Q1 2026 | 46% | +1182 points |
| Q4 2025 | 22% | +1259 points |
| Q3 2025 | 3.3% | +660 points |
| Q2 2025 | -424% | +319 points |
| Q1 2025 | -1135% | -166 points |
| Q4 2024 | -1238% | -654 points |
LQDA's operating margin was −117% last quarter, down 120 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over LQDA on cash flow, with more consistent year-over-year improvement.
LQDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $129.8M | +$140.5M |
| Q2 2026 | $69M | +$109.5M |
| Q1 2026 | $50.2M | +$81.2M |
| Q4 2025 | $42.2M | +$64.3M |
| Q3 2025 | -$10.7M | +$16.1M |
| Q2 2025 | -$40.5M | -$16.6M |
| Q1 2025 | -$31M | -$5.5M |
| Q4 2024 | -$22.1M | -$5.9M |
LQDA's free cash flow has turned positive after six years mostly in the red: $291M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LQDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LQDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -12% | -11.9M shares |
| 1 year | +3.7% | +3.2M shares |
| 3 years | +38% | +24.7M shares |
| 5 years | +72% | +37.4M shares |
| Available history | +340% | +69.2M shares |
LQDA has 90M diluted shares, up 3.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LQDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -1.7x | Net Cash |
| Q1 2026 | -4.8x | Net Cash |
LQDA has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LQDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.2 | Neutral |
| Stochastic | 37.7 | Neutral |
LQDA's weekly RSI is 52 (neutral) and its Stochastic is 38 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LQDA PE vs Healthcare Sector
| Metric | LQDA | Sector median | Relative |
|---|---|---|---|
| PE | 32x | 26x | 23% above |
| PE % | 16 | 29 | 13 pts below |
LQDA has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LQDA on trend strength, trading above more of its moving averages.
LQDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.6 | 33% above |
| 20 week MA | $63.0 | 7.7% below |
| 50 week MA | $51.4 | 13% above |
| 100 week MA | $34.9 | 67% above |
| 200 week MA | $22.3 | 160% above |
LQDA's trend is mixed: it's above four of its five weekly moving averages, and 160% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
LQDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.94 | $2.82 | -43% |
| 2021 | $2.82 | $4.67 | +66% |
| 2022 | $4.67 | $6.17 | +32% |
| 2023 | $6.17 | $12.0 | +95% |
| 2024 | $12.0 | $11.6 | -3.8% |
| 2025 | $11.6 | $34.4 | +197% |
| 2026 YTD | $34.4 | $58.1 | +69% |
LQDA has the edge over LLY on returns for 2026, with the stronger performance.